Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $1.95 Million Investment in Viridian Therapeutics, Inc. $VRDN

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 62,729 shares of the company’s stock, valued at approximately $1,952,000.

A number of other institutional investors have also recently bought and sold shares of VRDN. Vanguard Group Inc. boosted its position in Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after acquiring an additional 1,280,161 shares during the period. Commodore Capital LP boosted its position in Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares during the period. Jennison Associates LLC acquired a new stake in Viridian Therapeutics during the 4th quarter worth about $35,915,000. Wellington Management Group LLP boosted its position in Viridian Therapeutics by 314.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,122,532 shares of the company’s stock worth $24,224,000 after acquiring an additional 851,989 shares during the period. Finally, Fisher Asset Management LLC boosted its position in Viridian Therapeutics by 135.6% during the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock worth $25,922,000 after acquiring an additional 691,267 shares during the period.

Analyst Ratings Changes

A number of research firms have recently weighed in on VRDN. Stifel Nicolaus set a $39.00 price target on Viridian Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. Royal Bank Of Canada raised their price target on Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Evercore set a $26.00 price target on Viridian Therapeutics in a research note on Friday, May 15th. Finally, Wall Street Zen raised Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $17.69 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -5.33 and a beta of 0.82. The business’s 50-day simple moving average is $19.08 and its 200-day simple moving average is $26.51. Viridian Therapeutics, Inc. has a 52 week low of $13.18 and a 52 week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The firm’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.87) EPS. As a group, equities research analysts expect that Viridian Therapeutics, Inc. will post -3.71 earnings per share for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the acquisition, the director directly owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.40% of the stock is owned by company insiders.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.